Abstract:Background About 90% of mortality associated with cancer is attributable to metastatic disease. Thus, our ability to treat cancer is largely dependent on the capacity to prevent metastasis. Metabolic reprogramming is recognized to support cellular transformation and tumor initiation; however, whether or how metabolism supports metastasis remains an open question. This study seeks to identify metabolic predictors of metastasis, with the rationale that understanding metabolic changes will lead to novel insights into metastasis and perhaps new therapies to treat metastatic disease. Materials and methods A patient-derived xenograft model was used in which metastasis in mice strongly correlates with metastatic history of patient donors. Tumor cells were originally obtained from melanoma patients and passaged exclusively in highly immunocompromised mice [1]. In this study, 17 of such tumor lines were investigated including 6 lines with low metastatic potential, 9 high metastatic potential and 2 intermediate metastatic potential. Tumor cells were implanted subcutaneously into mice, yielding 62 tumors. 3-4 biopsies from each primary tumor were harvested, for a total of 185 samples. A mass spectrometry (MS)-based analytical platform was used to characterize >150 metabolites in each specimen. The relative abundance of metabolites that contribute most to the distinction of highly metastatic from inefficiently metastatic melanomas was examined using statistical tools. Results Unsupervised hierarchical clustering revealed that in every case, a given tumor biopsy was most closely related to all other biopsies descended from the same parental tumor. In addition, as a frequent mutation in melanoma, BRAFmutant tumors were easily distinguished from BRAF-wild type tumors by their metabolomic signatures. More importantly, several metabolic pathways were found altered significantly when metabolomics profiles between melanoma lines with high or low metastatic potentials were compared. Conclusions The MS-based metabolomic analysis of patient-derived melanoma xenografts demonstrates that tumors contain individual metabolomic identities that can be tracked. It may be possible to identify metabolomic features from primary tumors that predict various aspects of tumor biology, including the propensity to metastasize. The altered metabolic pathways in highly metastatic melanomas are potential therapeutic targets.

FADS2-mediated fatty acid desaturation and cholesterol esterification are signatures of metabolic reprogramming during melanoma progression

Multimodal Metabolic Imaging Reveals Pigment Reduction and Lipid Accumulation in Metastatic Melanoma

Mitochondrial Fatty Acid Oxidation is Not Vital for Melanoma Cell Proliferation and Migration

Alterations in Plasma Lipid Profiles Associated with Melanoma and Therapy Resistance

The Abundance of Metabolites Related to Protein Methylation Correlates with the Metastatic Capacity of Human Melanoma Xenografts

Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA

Identifying Metabolomic Features That Predict Metastasis of Melanoma from a Primary Site

Unraveling lipid metabolism reprogramming for overcoming drug resistance in melanoma

TCTN1 Induces Fatty Acid Oxidation to Promote Melanoma Metastasis

Metabolic Mechanisms Regulating Distinct Steps of the Melanoma Metastatic Cascade

FAK regulates E-cadherin expression via p-SrcY416/p-ERK1/2/p-Stat3Y705 and PPARγ/miR-125b/Stat3 signaling pathway in B16F10 melanoma cells

Dysregulated ceramides metabolism by fatty acid 2-hydroxylase exposes a metabolic vulnerability to target cancer metastasis

Phenotype-specific melanoma uptake of fatty acid from human adipocytes activates AXL and CAV1-dependent β-catenin nuclear accumulation

Temporal analysis of melanogenesis identifies fatty acid metabolism as key skin pigment regulator

Abstract 5541: The unique metabolite landscape of the aged microenvironment dictates melanoma migratory and invasive capacity

Adherent-to-suspension transition promotes melanoma metastatic dissemination

An MITF- and mTOR-dependent FLCN pathway suppresses TFE3-driven metastasis in melanoma

Lipid Metabolism in Cancer Progression and Therapeutic Strategies

Acyl-CoA synthetase long-chain 3-mediated fatty acid oxidation is required for TGFβ1-induced epithelial-mesenchymal transition and metastasis of colorectal carcinoma

New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations

Lysosomal acid ceramidase ASAH1 controls the transition between invasive and proliferative phenotype in melanoma cells